MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2174/0115680096510085261008045702

Медицинская библиотека · Current cancer drug targets · 2026

Distinct Patterns and Earlier Onset of Adverse Events in Young vs. Non-Young Breast Cancer Patients: A Real-World Analysis.

Li Yongxin, Zhu Zijun, Lu Jiatong, Li Yan, Shen Guoshuang, Zhao Jiuda

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

Age-related differences in Adverse Event (AE) reporting and reported Time to Onset (TTO) during systemic breast cancer treatment remain poorly characterized.

METHODS

We analyzed deduplicated reports from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) from January 2004 through December 2024. Reports involving systemic antineoplastic therapy were classified as Young Breast Cancer (YBC; <40 years) or Non-Young Breast Cancer (NYBC; ≥40 years). Analyses included covariate-adjusted logistic regression, 1:1 propensity-score matching, alternative age cutoffs, treatment-context sensitivity analyses, and adjusted bootstrap median regression. Multiplicity was controlled using Bonferroni correction.

RESULTS

Among 71,426 reports (YBC, 4,292; NYBC, 67,134), adjusted reporting odds differed for 10 System Organ Classes (SOCs) and 6 Preferred Terms (PTs); four SOC and four PT associations remained after matching. Unadjusted reported TTO was shorter for 5 SOCs and 8 PTs in YBC. After adjustment, only gastrointestinal disorders (-4.23 days; 95% CI, -7.11 to -1.34) and pyrexia (-5.22 days; 95% CI, -8.79 to -1.65) remained significant. Findings varied across age definitions and treatment contexts.

DISCUSSION: This is the first study to systematically characterize AE reporting patterns in YBC through an integrated pharmacovigilance framework. Using FAERS data, we compared YBC and NYBC in terms of reported AE timing and adjusted reporting odds across SOC and PT levels.

CONCLUSION

Selected AE reporting patterns differed by age, whereas most reported-TTO differences attenuated after adjustment. These exploratory reporting associations do not establish incidence, comparative toxicity, biological onset, or causality and require confirmation in datasets with exposure denominators and detailed treatment information.

Для цитирования: Li Yongxin, Zhu Zijun, Lu Jiatong, Li Yan, Shen Guoshuang, Zhao Jiuda. Distinct Patterns and Earlier Onset of Adverse Events in Young vs. Non-Young Breast Cancer Patients: A Real-World Analysis.. Current cancer drug targets. 2026. DOI: 10.2174/0115680096510085261008045702.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.